In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of <i>Aspergillus</i>, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of <i>Aspergillus</i>, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of <i>Aspergillus</i> spp., including azole–susc...

Full description

Bibliographic Details
Main Authors: Olga Rivero-Menendez, Juan Carlos Soto-Debran, Manuel Cuenca-Estrella, Ana Alastruey-Izquierdo
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Fungi
Subjects:
antifungals
ibrexafungerp
<i>Aspergillus</i>
<i>cyp</i>51A
cryptic
EUCAST
Online Access:https://www.mdpi.com/2309-608X/7/3/232

Internet

https://www.mdpi.com/2309-608X/7/3/232

Similar Items